Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors

Vascular endothelial growth factor A (VEGFA; hereafter referred to as VEGF) is a key regulator of physiological and pathological angiogenesis. Two families of VEGF isoforms are generated by alternate splice-site selection in the terminal exon. Proximal splice-site selection (PSS) in exon 8 results in pro-angiogenic VEGFxxx isoforms (xxx is the number of amino acids), whereas distal splice-site selection (DSS) results in anti-angiogenic VEGFxxxb isoforms. To investigate control of PSS and DSS, we investigated the regulation of isoform expression by extracellular growth factor administration and intracellular splicing factors. In primary epithelial cells VEGFxxxb formed the majority of VEGF isoforms (74%). IGF1, and TNFα treatment favoured PSS (increasing VEGFxxx) whereas TGFβ1 favoured DSS, increasing VEGFxxxb levels. TGFβ1 induced DSS selection was prevented by inhibition of p38 MAPK and the Clk/sty (CDC-like kinase, CLK1) splicing factor kinase family, but not ERK1/2. Clk phosphorylates SR protein splicing factors ASF/SF2, SRp40 and SRp55. To determine whether SR splicing factors alter VEGF splicing, they were overexpressed in epithelial cells, and VEGF isoform production assessed. ASF/SF2, and SRp40 both favoured PSS, whereas SRp55 upregulated VEGFxxxb (DSS) isoforms relative to VEGFxxx. SRp55 knockdown reduced expression of VEGF165b. Moreover, SRp55 bound to a 35 nucleotide region of the 3′UTR immediately downstream of the stop codon in exon 8b. These results identify regulation of splicing by growth and splice factors as a key event in determining the relative pro-versus anti-angiogenic expression of VEGF isoforms, and suggest that p38 MAPK-Clk/sty kinases are responsible for the TGFβ1-induced DSS selection, and identify SRp55 as a key regulatory splice factor.

[1]  Maryam Hamdollah-Zadeh,et al.  Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. , 2008, European journal of cancer.

[2]  S. Harper,et al.  Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  S. Harper,et al.  VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy , 2008, British Journal of Cancer.

[4]  E. Kleinerman,et al.  The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice , 2008, British Journal of Cancer.

[5]  D. Bates,et al.  Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma , 2007, British Journal of Cancer.

[6]  F. Eitner,et al.  Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. , 2007, Journal of the American Society of Nephrology : JASN.

[7]  Jung-Chun Lin,et al.  Cell stress modulates the function of splicing regulatory protein RBM4 in translation control , 2007, Proceedings of the National Academy of Sciences.

[8]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[9]  J. Wood,et al.  A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2 , 2006, Cellular and Molecular Life Sciences CMLS.

[10]  Yan Qiu,et al.  The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term. , 2006, Clinical science.

[11]  S. Harper,et al.  VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. , 2006, Molecular vision.

[12]  J. Venables.  Unbalanced alternative splicing and its significance in cancer , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[13]  A. Nash,et al.  The biology of vascular endothelial growth factor-B (VEGF-B). , 2006, Pulmonary pharmacology & therapeutics.

[14]  Leandro Quadrana,et al.  Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT , 2005, Nature Structural &Molecular Biology.

[15]  Christopher W. J. Smith.  Alternative Splicing— When Two’s a Crowd , 2005, Cell.

[16]  S. Harper,et al.  Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor , 2005, Diabetologia.

[17]  M. Rastaldi,et al.  Sam68-like mammalian protein 2, identified by digital differential display as expressed by podocytes, is induced in proteinuria and involved in splice site selection of vascular endothelial growth factor. , 2005, Journal of the American Society of Nephrology : JASN.

[18]  A. Kornblihtt,et al.  Promoter usage and alternative splicing. , 2005, Current opinion in cell biology.

[19]  F. Clark,et al.  Understanding alternative splicing: towards a cellular code , 2005, Nature Reviews Molecular Cell Biology.

[20]  K. Silina,et al.  Alterations of pre‐mRNA splicing in cancer , 2005, Genes, chromosomes & cancer.

[21]  K. Tsubota,et al.  TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts. , 2005, Experimental eye research.

[22]  B. O’Malley,et al.  Steroid Hormone Receptor Coactivation and Alternative RNA Splicing by U2AF65-Related Proteins CAPERα and CAPERβ , 2005 .

[23]  B. O’Malley,et al.  Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. , 2005, Molecular cell.

[24]  M. Rastaldi,et al.  Sam 68-Like Mammalian Protein 2 , Identified by Digital Differential Display as Expressed by Podocytes , Is Induced in Proteinuria and Involved in Splice Site Selection of Vascular Endothelial Growth Factor , 2005 .

[25]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[26]  W. Jin,et al.  Enhancer-Dependent Splicing of FGFR1 α-Exon Is Repressed by RNA Interference-Mediated Down-Regulation of SRp55 , 2004, Cancer Research.

[27]  C. Lechuga,et al.  TGF-beta1 modulates matrix metalloproteinase-13 expression in hepatic stellate cells by complex mechanisms involving p38MAPK, PI3-kinase, AKT, and p70S6k. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[28]  Marina Ziche,et al.  VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant , 2004, Cancer Research.

[29]  D. Helfman,et al.  A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. , 2004, Molecular biology of the cell.

[30]  Hiroshi Yamamoto,et al.  Possible participation of pICln in the regulation of angiogenesis through alternative splicing of vascular endothelial growth factor receptor mRNAs. , 2004, Endothelium : journal of endothelial cell research.

[31]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[32]  D. Gillatt,et al.  Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. , 2004, American journal of physiology. Renal physiology.

[33]  G. Neufeld,et al.  Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants , 1996, Cancer and Metastasis Reviews.

[34]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[35]  M. Mccarthy.  Antiangiogenesis drug promising for metastatic colorectal cancer , 2003, The Lancet.

[36]  M. Lai,et al.  Differential effects of hyperphosphorylation on splicing factor SRp55. , 2003, The Biochemical journal.

[37]  John I. Loewenstein,et al.  Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. , 2003, Ophthalmology.

[38]  F. Otsuka,et al.  PDGF‐BB Induces MAP Kinase Phosphorylation and VEGF Expression in Neurofibroma‐Derived Cultured Cells from Patients with Neurofibromatosis 1 , 2002, The Journal of dermatology.

[39]  D. Gillatt,et al.  VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. , 2002, Cancer research.

[40]  A. Kornblihtt,et al.  Alternative splicing: multiple control mechanisms and involvement in human disease. , 2002, Trends in genetics : TIG.

[41]  M. O'hare,et al.  A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. , 2002, Journal of the American Society of Nephrology : JASN.

[42]  D. Gillatt,et al.  VEGF 165 b , an Inhibitory Splice Variant of Vascular Endothelial Growth Factor , Is Down-Regulated in Renal Cell Carcinoma 1 , 2002 .

[43]  M. Benito,et al.  Activation of p38MAPK by TGF‐β in fetal rat hepatocytes requires radical oxygen production, but is dispensable for cell death , 2001, FEBS letters.

[44]  M. Dake,et al.  Vascular endothelial growth factor enhances atherosclerotic plaque progression , 2001, Nature Medicine.

[45]  Peter Carmeliet,et al.  VEGF gene therapy: stimulating angiogenesis or angioma-genesis? , 2000, Nature Medicine.

[46]  D. Charnock-Jones,et al.  The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. , 2000, Human reproduction.

[47]  A. Krainer,et al.  The Mkk3/6-p38–Signaling Cascade Alters the Subcellular Distribution of Hnrnp A1 and Modulates Alternative Splicing Regulation , 2000, The Journal of cell biology.

[48]  G. Edelman,et al.  Differential regulation by multiple promoters of the gene encoding the neuron-restrictive silencer factor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  T. Pawson,et al.  The Protein Kinase Clk/Sty Directly Modulates SR Protein Activity: Both Hyper- and Hypophosphorylation Inhibit Splicing , 1999, Molecular and Cellular Biology.

[50]  A. Kornblihtt,et al.  Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer. , 1999, Molecular cell.

[51]  J. Manley,et al.  Phosphorylated RNA polymerase II stimulates pre-mRNA splicing. , 1999, Genes & development.

[52]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  J. Klekamp,et al.  Vascular endothelial growth factor expression is decreased in rat lung following exposure to 24 or 48 hours of hyperoxia: implications for endothelial cell survival. , 1998, Chest.

[54]  G. Siemeister,et al.  Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression , 1997, Oncogene.

[55]  B. Keyt,et al.  Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. , 1997, Archives of biochemistry and biophysics.

[56]  T. Maniatis,et al.  Common themes in the function of transcription and splicing enhancers. , 1997, Current opinion in cell biology.

[57]  Tom Misteli,et al.  The dynamics of a pre-mRNA splicing factor in living cells , 1997, Nature.

[58]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[59]  K. Matsumoto,et al.  Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. , 1997, Nephron.

[60]  E. Haber,et al.  Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. , 1996, The Journal of clinical investigation.

[61]  C. Patterson,et al.  Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. , 1996, Endocrinology.

[62]  S. Kondo,et al.  Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. , 1996, Biochemical and biophysical research communications.

[63]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[64]  D. Mukhopadhyay,et al.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation , 1995, Nature.

[65]  C. Patterson,et al.  Induction of Vascular Endothelial Growth Factor Gene Expression by Interleukin-1 in Rat Aortic Smooth Muscle Cells (*) , 1995, The Journal of Biological Chemistry.

[66]  K. Alitalo,et al.  Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. , 1994, The Journal of biological chemistry.

[67]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[68]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[69]  J. Folkman,et al.  Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. , 1990, Growth factors.

[70]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.